Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 100 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty 10 microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; hydrochloric acid - copd trimbow 100/6/10 is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid (ics) and a long-acting beta2-agonist (laba) or a combination of a laba and a long-acting muscarinic antagonist (lama). asthma trimbow 100/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Malta - Ingliż - Medicines Authority

central procurement & supplies unit - beclometasone dipropionate - nasal spray, suspension - beclometasone dipropionate 50 µg - nasal preparations

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

apotex sa-nv - beclometasone dipropionate 50 µg/dose - nasal spray, suspension - 0,05 % - beclometasone dipropionate 50 µg/dose - beclometasone

Malta - Ingliż - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - beclometasone dipropionate - nasal spray, suspension - beclometasone dipropionate 50 µg - drugs for obstructive airway diseases

Iżrael - Ingliż - Ministry of Health

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised solution - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.copd :symptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

3m health care limited - beclometasone dipropionate - pressurised inhalation soln - 50 %v/v

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

3m health care limited - beclometasone dipropionate - pressurised inhalation soln - 100 %v/v

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

3m health care limited - beclometasone dipropionate - pressurised inhalation soln - 100 %v/v

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

3m health care limited - beclometasone dipropionate - pressurised inhalation soln - 50 %v/v

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - beclometasone dipropionate - inhalation powder - 100microgram